Context Therapeutics Inc. (CNTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US21077P1084
Context Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -39.70 m USD |
| EBIT | -39.50 m USD |
| Net income | -36.12 m USD |
| Diluted EPS – continuing operations | -0.38 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
More stocks
- Jaguar Uranium Corp. (JAGU)
- Medalist Diversified, Inc. (MDRR)
- INTELLINETICS, INC. (INLX)
- UPAY (UPYY)
- RETRACTABLE TECHNOLOGIES INC (RVP)
- DYNARESOURCE, INC. (DYNR)
- REGIONAL HEALTH PROPERTIES, INC (RHEPB)
- Teads Holding Co. (TEAD)
- Cosmos Health Inc. (COSM)
- ARK RESTAURANTS CORP (ARKR)
- Beam Global (BEEM)
- Vicapsys Life Sciences, Inc. (VICP)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.